EUVIMEDEUVIMED entdecken
Open Access

Nitric oxide-releasing prodrug for the treatment of complex Mycobacterium abscessus infections

Rebecca A McDonald, Sarah G Nagy iD, Madyson Chambers, Chris A Broberg, Mona J R Ahonen, Mark H Schoenfisch iD

Antimicrobial Agents and Chemotherapy · 07.02.2024 · 68 (2)

DOI: 10.1128/aac.01327-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.02.2024. Verfasst von Rebecca A McDonald und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vast Therapeutics, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Prodrugs, Mycobacterium Infections, Nontuberculous, Mycobacterium. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cystic Fibrosis Foundation (CFF), KnowBIO, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-tuberculosis mycobacteria (NTM) can cause severe respiratory infection in patients with underlying pulmonary conditions, and these infections are extremely difficult to treat. In this report, we evaluate a nitric oxide (NO)-releasing prodrug [methyl tris diazeniumdiolate (MD3)] against a panel of NTM clinical isolates and as a treatment for acute and chronic NTM infections in vivo . Its efficacy in inhibiting growth or killing mycobacteria was explored in vitro alongside evaluation of the impact to primary human airway epithelial tissue. Airway epithelial tissues remained viable after exposure at concentrations of MD3 needed to kill mycobacteria, with no inherent toxic effect from drug scaffold after NO liberation. Resistance studies conducted via serial passage with representative Mycobacterium abscessus isolates demonstrated no resistance to MD3. When administered directly into the lung via intra-tracheal administration in mice, MD3 demonstrated significant reduction in M. abscessus bacterial load in both acute and chronic models of M. abscessus lung infection. In summary, MD3 is a promising treatment for complex NTM pulmonary infection, specifically those caused by M. abscessus , and warrants further exploration as a therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsMycobacterium Infections, NontuberculousMycobacteriumHumansAnimalsMiceNitric OxideAnti-Bacterial AgentsNontuberculous MycobacteriaMicrobial Sensitivity Tests

Stichwörter der Autor:innen

M. abscessusNTMdiazeniumdiolatemycobacterianitric oxideprodrugtherapeutic

Substanzen

Nitric OxideAnti-Bacterial AgentsProdrugs

Autor:innen und Institutionen

  • Vast Therapeutics, Durham, North Carolina, USA.
  • Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.

ORCID-Profile: Sarah G Nagy, Mark H Schoenfisch

Förderung

  • Cystic Fibrosis Foundation (CFF)
  • KnowBIO, LLC

Zitieren

APA

McDonald, R. A., Nagy, S. G., Chambers, M., Broberg, C. A., Ahonen, M. J. R., & Schoenfisch, M. H. (2024). Nitric oxide-releasing prodrug for the treatment of complex Mycobacterium abscessus infections. Antimicrobial Agents and Chemotherapy, 68(2). https://doi.org/10.1128/aac.01327-23

Vancouver

McDonald RA, Nagy SG, Chambers M, Broberg CA, Ahonen MJR, Schoenfisch MH. Nitric oxide-releasing prodrug for the treatment of complex Mycobacterium abscessus infections. Antimicrobial Agents and Chemotherapy. 2024;68(2). doi:10.1128/aac.01327-23

BibTeX
@article{McDonald2024,
  author = {McDonald, Rebecca A and Nagy, Sarah G and Chambers, Madyson and Broberg, Chris A and Ahonen, Mona J R and Schoenfisch, Mark H},
  title = {Nitric oxide-releasing prodrug for the treatment of complex Mycobacterium abscessus infections},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {2},
  doi = {10.1128/aac.01327-23}
}
Kostenlos starten →